Theralase Technologies Inc
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 15
- Market Cap
- -
- Introduction
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
- Conditions
- Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Theralase® Technologies Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT03945162
- Locations
- 🇺🇸
Site 02-012 - University of Chicago, Chicago, Illinois, United States
🇺🇸Site 02-008 - MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
🇺🇸Site 02-006 - Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
- Conditions
- Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
- Interventions
- Drug: TLD1433 infusion and photodynamic therapy (PDT) treatment
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Theralase® Technologies Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03053635
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
News
Theralase Technologies Reports Promising Phase 2 Bladder Cancer Data and Outlines Funding Strategy
Theralase Technologies announced a 61.9% complete response rate in its Phase 2 bladder cancer study, with a 43.6% duration of response at 450 days.